Sign In
Buy EW
$86.00
-1.66 (-1.89%)
At Close: Jun 03, 2026
Edwards Lifesciences Reports First Quarter Results
04:15pm, Wednesday, 23'rd Apr 2025
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% ad
Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics
10:20am, Friday, 18'th Apr 2025
Evaluate the expected performance of Edwards Lifesciences (EW) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key
Eight-Year Data Confirm Long-Term Durability of Edwards' RESILIA Tissue
08:00am, Friday, 18'th Apr 2025
CAIRO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technolog
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings
09:35am, Thursday, 17'th Apr 2025
EW's first-quarter 2025 performance is likely to have gained from growth drivers across its businesses amid macroeconomic headwinds.
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025
07:05am, Wednesday, 16'th Apr 2025
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and w
Edwards SAPIEN M3 Receives CE Mark, Becoming World's First Transfemoral Transcatheter Mitral Valve Replacement System
08:00am, Monday, 14'th Apr 2025
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company's SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of
CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology's (ACC) Annual Scientific Session &
Edwards Lifesciences: Double-Digit Top Line And EPS Growth Ahead
11:51pm, Saturday, 22'nd Mar 2025
Health Care and Energy sectors outperform in 2025, with the Health Care Select Sector SPDR Fund ETF up 7% YTD, while Edwards Lifesciences lags. Despite a solid Q4 earnings beat, EW's shares remain und
SUNNYVALE, Calif.--(BUSINESS WIRE)--Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner an
Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference
07:05am, Tuesday, 25'th Feb 2025
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025. Scott Ulle
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
10:26am, Thursday, 20'th Feb 2025
EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.
Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength
02:51pm, Wednesday, 12'th Feb 2025
On Tuesday, Edwards Lifesciences EW reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This represents a 9% year-over-year growth, supported by gains in all produc
EW Stock Up on Q4 Earnings and Revenue Beat, Margins Crash
08:35am, Wednesday, 12'th Feb 2025
Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart?
Edwards Lifesciences Corporation (EW) Q4 2024 Earnings Call Transcript
09:46pm, Tuesday, 11'th Feb 2025
Edwards Lifesciences Corporation (NYSE:EW ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Mark Wilterding - Senior Vice President, Investor Relations Bernard Zovig
Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics
07:01pm, Tuesday, 11'th Feb 2025
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare wit
